Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials

Area of Science:

• Oncology
• Clinical Trials
• Biostatistics

Background:

• Adjuvant chemotherapy for operable breast cancer is a subject of ongoing global debate.
• Assessing its true efficacy requires rigorous analysis of pooled data.

Purpose of the Study:

• To systematically evaluate the impact of adjuvant chemotherapy on survival outcomes in operable breast cancer.
• To quantify the benefits of chemotherapy using pooled data from randomized controlled trials.

Main Methods:

• Conducted a meta-analysis of published randomized controlled trials (RCTs) with at least two years of follow-up.
• Calculated pooled estimates for relapse-free survival (RFS) and overall survival (OS) rates.
• Stratified analysis based on the number of chemotherapeutic agents used.

Main Results:

• Adjuvant chemotherapy significantly improved RFS by 12.5% at three years and 8% at five years.
• Multi-agent chemotherapy regimens demonstrated a greater positive impact on RFS.
• A significant OS advantage of 4% at three years was observed specifically for multi-agent trials.

Conclusions:

• Adjuvant chemotherapy, particularly multi-agent regimens, offers a tangible survival benefit for operable breast cancer patients.
• This systematic meta-analysis provides robust evidence to inform the therapeutic controversy surrounding adjuvant chemotherapy.
• The methodology highlights the value of pooled RCT data for resolving clinical questions.